How much does stem cell therapy for Macular Degeneration & Vision cost? (2026)
The comparison dataset stores a Bulgaria planning observation of €3,000–€8,000 for treatment, compiled from cited public commercial sources. It is not a quotation from Stem Plus, and different products, doses, visits and inclusions must not be treated as equivalent. The stored registry query contains 44 Macular Degeneration & Vision records. Registration does not mean that a study is recruiting, that a person is eligible, or that treatment and travel are free; verify the current record and sponsor-cost terms directly.
Age-related macular degeneration (AMD) and inherited retinal diseases can damage photoreceptors or the retinal pigment epithelium (RPE), but they are distinct conditions with different causes and established management. Investigational cell approaches include RPE or retinal progenitor products derived from sources such as induced pluripotent stem cells (iPSC). Laboratory differentiation or integration hypotheses do not establish restored vision in people. Product identity, surgical route, immune risk and disease stage are critical. The registry table on this page lists relevant studies and their current recruitment status.
What drives the cost for Macular Degeneration & Vision
Private investigational retinal cell procedures can involve separate charges for surgery, imaging, laboratory testing, immunological monitoring, travel and treatment of complications. Prices do not indicate regulatory approval or expected visual benefit, and bilateral treatment should not be assumed appropriate. Patients should request an itemised written quote and verify sponsor, insurer and patient responsibilities. Established retinal care must not be delayed.
Human retinal cell-therapy studies are early and heterogeneous, involving different diseases, cell products, surgical routes and endpoints. Small-cohort safety observations and exploratory visual changes do not establish durable vision stabilisation or restoration. Imaging, light sensitivity and visual-acuity measures should not be merged into a single response claim. No pooled response rate is published here because the studies are too heterogeneous for a single figure to be meaningful. The registered studies and their own prespecified endpoints are listed in the registry table on this page.
Macular Degeneration & Vision cost by country — comparison (2026)
| Location | Indicative treatment cost | Regulation |
|---|---|---|
| Bulgaria (EU) · e.g. Stem Plus | €3,000–€8,000 | Verify provider and laboratory certificates |
| USA | €4,600–€46,000 | Non-EU; verify provider and product status |
| UK | €4,880–€49,000 | Non-EU; verify provider and product status |
| Germany | €11,000–€36,700 | EU member state; verify provider and product status |
| Switzerland | €20,000–€40,000 | Non-EU; verify provider and product status |
| Mexico | €3,000–€12,000 | Non-EU; verify provider and product status |
| India | €3,000–€8,000 | Non-EU; verify provider and product status |
| Serbia | €7,000–€31,000 | Non-EU; verify provider and product status |
| Turkey | €6,000–€18,000 | Non-EU; verify provider and product status |
| Thailand | €8,000–€20,000 | Non-EU; verify provider and product status |
| Panama | €15,000–€27,000 | Non-EU; verify provider and product status |
Price varies with cell type, dose, number of sessions, diagnostics, supportive care and follow-up. A lower range does not establish equivalent quality or outcome. Request a fixed written quote and verify the therapy and provider with the relevant authorities. Check registered trials before paying privately.
Macular Degeneration & Vision cost — common questions
Why is Macular Degeneration & Vision stem-cell treatment so much cheaper in Bulgaria?
The collected commercial ranges differ, but they may describe different products, doses, visits and inclusions. A lower quote does not establish equivalent quality, evidence or regulatory status.
Is a cheaper programme riskier?
Price alone cannot establish risk. Verify the exact treatment status, provider and manufacturing authorisations, product identity, release testing, adverse-event plan and primary evidence.
Does the price include travel and hotel?
The €3,000–€8,000 range covers the medical programme. Add flights, hotel and recovery with our calculator for your true all-in cost from your city.
Will I get a fixed quote, or an open-ended bill?
Ask for a written quotation after clinical review, with the exact product, inclusions, exclusions, cancellation terms and circumstances in which charges may change. A website estimate is not a binding quote.
Sources & further reading
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
- Open clinical trials for Macular Degeneration & Vision (ClinicalTrials.gov) ↗
- Peer-reviewed research on PubMed ↗
- ISSCR patient guide — what to ask ↗
- FDA consumer warning on stem-cell therapies ↗
- EMA — advanced-therapy (ATMP) framework ↗
Indicative ranges for planning, compiled from public market data; confirmed pricing follows a medical review. Not medical advice.